Creatinine =< 1.5 times ULN
Total bilirubin equal to or less than 1.5 times the ULN
Creatinine less than 1.5 times the ULN
Aspartate aminotransferase (AST) > 2.5 times ULN if no demonstrable liver metastases, or > 5 times ULN in presence of liver metastases
PT ? 1.5 times institutional ULN
PTT ? 1.5 times institutional ULN
Serum creatinine =< 2 times ULN; timeline: within 3 weeks prior to enrollment
Within 30 days prior to enrollment: Total bilirubin equal to or less than 1.5 times the ULN
Within 30 days prior to enrollment: Creatinine less than 1.5 times the ULN
Total serum bilirubin ?1.5 times ULN
Total bilirubin < 1.5 times the upper limit of normal (ULN) if no liver metastases or < 3 times the ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinemia) or liver metastases
Total bilirubin < 1.5 times the upper limit of normal (ULN) if no liver metastases or < 3 times the ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinemia) or liver metastases
Total serum bilirubin > 1.5 times ULN
Bilirubin =< 1.5 times ULN before starting therapy
Aspartate aminotransferase > 2.5 times the ULN if no demonstrable liver metastases or > 5 times the ULN in the presence of liver metastases.
Total bilirubin > 1.5 times the ULN if no liver metastases or > 3 times the ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.
Total bilirubin >1.5 times ULN
Creatinine < 1.5 times ULN.
Has liver fibrosis either determined by imaging or laboratory testing (i.e. total serum bilirubin > 1.5 times ULN, AST and ALT > 2.5 times ULN, INR > 1.5 times ULN, albumin < 2.5 mg/dl)
Total bilirubin < 1.5 times ULN if no liver metastases or < 3 times ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinaemia) or liver metastases obtained =< 14 days prior to study initiation
Total bilirubin >1.5 times ULN if no liver metastases or 3 times ULN in the presence of liver metastases or documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia)
Total bilirubin > 1.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or > 3 times ULN in the presence of documented Gilbert’s syndrome or liver metastases
Total serum bilirubin ? 1.5 times the ULN
Bilirubin =< 1.5 ULN (for patients with liver metastasis up to =< 5 times of ULN is allowed)
Total bilirubin =< 1.5 times the institutional upper limit of normal (ULN) (or =< 3 times ULN in case of liver metastasis or Gilbert syndrome)
Total bilirubin </=2 times the ULN
Creatinine =< 1.5 times ULN
Creatinine < 1.5 times ULN
Aspartate aminotransferase (AST) >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
Creatinine =< 1.5 times ULN
Total bilirubin ?1.5 times ULN; and
Total bilirubin ?1.5 times ULN; and
Aspartate aminotransferase > 2.5 times ULN if no demonstrable liver metastases or > 5 times ULN in the presence of liver metastases
Total bilirubin > 1.5 times ULN if no liver metastases or > 3 times ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinemia) or liver metastases
ALT/AST ? 2.5 times ULN, or < 5 times ULN for subjects with liver metastases
Within 14 days of first dose of study drug administration: Total bilirubin =< 1.5 times the institutional upper limit of normal (ULN) (or =< 3 times ULN in case of liver metastasis)
ALT/AST ? 2.5 times ULN, or < 5 times ULN for subjects with liver metastases
EXCLUSION CRITERIA FOR ENROLLMENT: Total bilirubin > 3 times the ULN
Failure to meet the following laboratory levels on preoperative screening:\r\n* Platelet count >= 100,000 mm^3\r\n* Hemoglobin >= 10 g/dl\r\n* Prothrombin time (PT) =< 1.5 times upper limit of laboratory normal (ULN)\r\n* Activated partial thromboplastin time =< 1.5 times ULN\r\n* Serum creatinine < 2.5 times ULN
Serum bilirubin < 1.5 times ULN
total bilirubin 1.5 times greater than the ULN, except if related to ALL/LBL,
Creatinine and total bilirubin ? 1.5 times ULN
Creatinine =< 1.5 times ULN
Bilirubin =< 1.5 times ULN
Bilirubin < 2 times ULN (performed within 14 days prior to registration)
Alanine aminotransferase > 2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or > 5 times ULN in the presence of liver metastases; aspartate aminotransferase > 2.5 times ULN if no demonstrable liver metastases or > 5 times ULN in the presence of liver metastases
Total bilirubin > 1.5 times ULN if no liver metastases or > 3 times ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinemia) or liver metastases
AST and ALT < 5 times ULN; ALP < 5 times ULN; Bilirubin ? 1.5 times ULN; Creatinine ? 1.5 times ULN and eGFR ? 50.
ALT and AST >3.0 times the ULN if no liver involvement or >5 times the ULN with liver involvement.
Serum bilirubin < 1.5 times the upper limit of normal (ULN); unless due to Gilbert’s syndrome (in which < 2 times ULN acceptable)
Bilirubin > 1.5 times ULN
Total bilirubin <1.5 times ULN
ALT/AST ? 2.5 times ULN, or < 5 times ULN for subjects with liver metastases
Serum direct bilirubin (DB) =< 1.5 times ULN within 14 days prior to admission
Creatinine =< 1.5 times ULN
ALT/AST less than or equal to 3 times ULN or less than or equal to 5 times ULN in the setting of liver metastases.
Total bilirubin less =< to 1 times ULN
Total serum/plasma bilirubin ?1.5 times ULN.
Total bilirubin < 1.5 times ULN
Liver transaminases within 2.5 times ULN
Bilirubin < 1.5 times ULN, unless bilirubin elevation is related to Gilbert’s syndrome for which bilirubin must be < 4 times ULN
Alkaline phosphatase ? 2.5 times ULN (? 5 times ULN for patients with liver metastases);
Total bilirubin >= 1.5 times ULN
Total bilirubin =< 1.5 times ULN*
Serum bilirubin levels =< 1.5 times the ULN range for the laboratory
Bilirubin no greater than 1.5 times ULN
Bilirubin < 2 times ULN
Total bilirubin =< 2.5 times ULN
Total bilirubin should be < 1.5 times ULN
Ammonia < 1.5 times ULN
SGOT < 2.5 times ULN
Bilirubin =< 1.5 times ULN
Total bilirubin =< 1.5 times ULN and stable X 1 month
Serum bilirubin =< 2 times ULN
Inadequate hepatic function (Total bilirubin > 1.5 times the institutional upper limit of normal (ULN) (except known Gilbert's syndrome); Alanine transaminase (ALT) or aspartate transaminase (AST) > 2.5 times the institutional ULN. ALT or AST up to 3 times the institutional ULN permitted if total bilirubin is normal
Carcinoembryonic antigen (CEA)</=3 times the ULN
PT or aPTT < 1.5 times the ULN
Creatinine >= 1.5 times ULN
Hepatic: Bilirubin less than or equal to 1.5 times upper limits of normal (ULN), ALT, and aspartate transferase (AST) less than or equal to 2.0 times ULN. If the liver has tumor involvement AST and ALT equaling less than or equal to 5 times ULN are acceptable.
ALT < 3 times ULN and bilirubin < 1.5 mg/dL
Serum ALT < 2.5 times the ULN.
Bilirubin < 1.5 times ULN
Total bilirubin < 1.5 times ULN
Urea and serum creatinine < 2.5 times ULN
Total bilirubin < 1.5 times ULN
AST ? 2.5 times ULN (? 5 times ULN for patients with liver metastases);
Alkaline phosphatase ? 2.5 times ULN (? 5 times ULN for patients with liver metastases);
Obtained within 14 days prior to initiation of treatment: Serum creatinine =< 1.5 times ULN
Bilirubin ? 2.0 mg/dl; AST and ALT < 5.0 times the ULN
DONOR: Total creatinine kinase > 2 times the ULN
Total bilirubin level greater than 3 times the ULN
Aspartate aminotransferases (AST) =< 3 times ULN
DONOR: Total creatinine kinase > 2 times the ULN
Has laboratory results that are outside of normal limits at screening, as follows: a) Moderate or severe liver dysfunction, as defined as: Aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN), OR Alanine aminotransferase (ALT) > 5 times the ULN, OR Serum total bilirubin >2.5 times the ULN, OR AST or ALT > 3 times ULN with total bilirubin > 2 times ULN; b) Calculated creatinine clearance <30 mL/min.
Serum creatinine within 1.5 times the institution’s ULN
Bilirubin < 2 times ULN, performed within 28 days prior to registration
Total serum/plasma bilirubin ?1.5 times ULN.
